Novartis (NVS)
(Delayed Data from NYSE)
$115.97 USD
+0.27 (0.23%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $116.01 +0.04 (0.03%) 4:26 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Income Statements
Fiscal Year end for Novartis AG falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 46,660 | 51,828 | 52,877 | 49,898 | 48,677 |
Cost Of Goods | 12,472 | 15,486 | 15,867 | 15,121 | 14,425 |
Gross Profit | 34,188 | 36,342 | 37,010 | 34,777 | 34,252 |
Selling & Adminstrative & Depr. & Amort Expenses | 24,419 | 27,145 | 25,321 | 24,625 | 25,166 |
Income After Depreciation & Amortization | 9,769 | 9,197 | 11,689 | 10,152 | 9,086 |
Non-Operating Income | 209 | 11 | 15,259 | 595 | 704 |
Interest Expense | 855 | 837 | 811 | 869 | 850 |
Pretax Income | 9,123 | 8,371 | 26,137 | 9,878 | 8,940 |
Income Taxes | 551 | 1,416 | 2,119 | 1,807 | 1,793 |
Minority Interest | 4 | 0 | -3 | -1 | 5 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 8,572 | 6,955 | 24,018 | 8,071 | 7,147 |
Extras & Discontinued Operations | 6,282 | 0 | 0 | 0 | 4,590 |
Net Income (GAAP) | 14,850 | 6,955 | 24,021 | 8,072 | 11,732 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 18,152 | 9,197 | 17,764 | 16,281 | 14,874 |
Depreciation & Amortization (Cash Flow) | 8,383 | 0 | 6,075 | 6,129 | 5,788 |
Income After Depreciation & Amortization | 9,769 | 9,197 | 11,689 | 10,152 | 9,086 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2,077.48 | 2,197.00 | 2,260.00 | 2,296.00 | 2,319.00 |
Diluted EPS Before Non-Recurring Items | 6.90 | 6.10 | 6.24 | 5.75 | 5.24 |
Diluted Net EPS (GAAP) | 7.10 | 3.17 | 10.63 | 3.52 | 5.06 |
Fiscal Year end for Novartis AG falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 12,872.00 | 12,120.00 | 7,424.00 | 12,092.00 | 13,936.00 |
Cost Of Goods | 3,173.00 | 3,096.00 | 1,083.00 | 3,117.00 | 4,341.00 |
Gross Profit | 9,699.00 | 9,024.00 | 6,341.00 | 8,975.00 | 9,595.00 |
SG&A, R&D, and Dept/Amort Expenses | 5,685.00 | 5,651.00 | 4,110.00 | 7,213.00 | 6,675.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 4,014.00 | 3,373.00 | 2,231.00 | 1,762.00 | 2,920.00 |
Non-Operating Income | 73.00 | -23.00 | 29.00 | 12.00 | 73.00 |
Interest Expense | 246.00 | 221.00 | 198.00 | 222.00 | 224.00 |
Pretax Income | 3,841.00 | 3,129.00 | 2,062.00 | 1,552.00 | 2,769.00 |
Income Taxes | 595.00 | 441.00 | -386.00 | 39.00 | 452.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 2.00 | 1.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 3,246.00 | 2,688.00 | 2,448.00 | 1,513.00 | 2,317.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 6,032.00 | 250.00 | 0.00 |
Net Income (GAAP) | 3,246.00 | 2,688.00 | 8,480.00 | 1,761.00 | 2,316.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2,046.00 | 2,051.90 | 2,048.30 | 2,075.00 | 2,095.00 |
Diluted EPS Before Non-Recurring Items | 1.97 | 1.80 | 1.53 | 1.74 | 1.83 |
Diluted Net EPS (GAAP) | 1.59 | 1.31 | 4.06 | 0.85 | 1.11 |